TG Immunopharma’s bispecific antibody receives FDA clearance to enter clinic for solid tumors
June 19, 2023
TG Immunopharma Co. Ltd. has announced clearance by the FDA for a clinical trial of TGI-6, a bispecific antibody targeting unique tumor-associated antigens (TAA) and CD3 molecules simultaneously, for solid tumors.
